Repligen Corporation $RGEN Shares Acquired by Strs Ohio

Strs Ohio increased its holdings in Repligen Corporation (NASDAQ:RGEN) by 8.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 54,760 shares of the biotechnology company’s stock after purchasing an additional 4,498 shares during the period. Strs Ohio owned 0.10% of Repligen worth $6,452,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in RGEN. Measured Wealth Private Client Group LLC acquired a new stake in Repligen in the 3rd quarter worth about $29,000. Bayforest Capital Ltd purchased a new position in shares of Repligen during the 4th quarter worth about $32,000. Rachor Investment Advisory Services LLC purchased a new position in shares of Repligen during the 4th quarter worth about $33,000. Los Angeles Capital Management LLC acquired a new stake in shares of Repligen in the fourth quarter worth approximately $36,000. Finally, Farther Finance Advisors LLC boosted its position in shares of Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 128 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on RGEN shares. Barclays upped their price target on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Jefferies Financial Group reissued a “hold” rating and set a $142.00 price objective on shares of Repligen in a research note on Tuesday, May 5th. Royal Bank Of Canada initiated coverage on Repligen in a report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective for the company. Wolfe Research assumed coverage on Repligen in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 target price on the stock. Finally, JPMorgan Chase & Co. reduced their target price on Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $164.64.

Repligen Price Performance

RGEN opened at $142.40 on Monday. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $175.77. The company has a 50 day moving average of $123.84 and a two-hundred day moving average of $134.61. The company has a market cap of $8.03 billion, a P/E ratio of 158.22, a P/E/G ratio of 2.74 and a beta of 1.06. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.25 million for the quarter, compared to analyst estimates of $192.05 million. During the same quarter in the previous year, the business posted $0.39 EPS. The business’s quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, analysts expect that Repligen Corporation will post 1.99 earnings per share for the current year.

Insider Activity at Repligen

In other Repligen news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.60% of the stock is currently owned by corporate insiders.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.